Introduction
Ras is a family of closely related small (M r 21 000) proteins that includes H-ras, N-ras, K-ras2A, and Kras2B. These proteins, which are bound to guanosine 5 0 -triphosphate in their active form and guanosine 5 0 -diphosphate in the inactive form, function as intermediates in signal transduction in the inner cell membrane (Barbacid, 1987) . Mutations in different ras genes have been found in multiple types of human cancer, suggesting that ras plays a key role in the development of cancer (Bos, 1989; Shield et al, 2000) . Mutations in the different Ras genes also show remarkable tissue selectivity. For example, K-ras mutations are common in human pancreatic cancer (Almoguera et al., 1988) and colon cancer (Bos et al., 1987a; Forrester et al., 1987) ; H-ras mutations have been found in human bladder cancer (Visvanathan et al., 1988) , and mutations in N-ras have been observed in acute myloid leukemia (Bos et al., 1987b) .
The reported frequency of ras mutation in human ovarian cancer varies considerably, partly because human ovarian cancer is very heterogeneous. Human ovarian cancer includes several distinct histotypes (serous, mucinous, endometrioid, and clear cell type), and each histotype can be further classified as benign, borderline, or malignant. K-ras mutations have been found in mucinous tumors of the ovary (detected in 11-75% of cases) and, to a lesser extent, in nonmucinous tumors (detected in 5-36% of cases) (Enomoto et al., 1991; Mok et al., 1993; Teneriello et al., 1993; Ichikawa et al., 1994; Cuatrecasas et al., 1997 Cuatrecasas et al., , 1998 . A recent study suggested that K-ras and BRAF are mutated at a high frequency in boderline and low-grade serous ovarian carcinomas (Singer et al., 2003) . Mutations of H-ras in ovarian tumors seem to be less common; in one study, the incidence of H-ras mutations was approximately 6% (Varras et al., 1999) ; however, activation of ras-signaling pathway without ras mutation is common in high-grade serous ovarian cancer, the most common type of ovarian carcinomas (Patten et al., 1998) . While most studies focused on mutation analysis of K-ras gene, the effects of H-ras, either due to mutation or activated H-ras pathway without mutation, in ovarian tumors are largely unknown.
In this study, we used retrovirus-mediated expression of siRNAs against several sequences of the H-ras gene to selectively silence mRNA expression from gene containing H-rasV 12 mutation or wild-type H-ras in ovarian cancer cell lines, with the goal of examining the effects of such silencing on cellular transformation in vitro and tumorgrowth in vivo and the role of H-ras in human ovarian cancer.
Results

Development of the retrovirus-mediated siRNA expression system
The retroviral constructs used are shown schematically in Figure 1a . The pLNCX/U6 vector control was constructed by replacing the cytomegalovirus promoter with a U6 promoter, which is directed by RNA polymerase III and directs the transcription that terminates at a run of 4-5 Ts to make it possible to synthesize RNA with defined ends. We first used green fluorescence protein (GFP) as a target reporter gene to test the efficiency of retrovirus-mediated gene silencing. We ligated the U6 promoter and the GFP siRNA into the retroviral expression pLNCX vector to pLNCX/U6/ gfp/siRNA. The retrovirus construct, named pLNCX/ U6/gfp/siRNA, contains a U6 promoter that directs the synthesis of oligonucleotides in an inverted repeat with six nucleotides (nt) for its loop, with five Ts added at the end to serve as a termination signal for RNA polymerase III. The RNA is expected to fold back to form a hairpin loop structure after being transcribed. Active gfp/siRNA is a 21-nt-long double-stranded RNA (dsRNA) with a symmetrical 2-to 3-nt overhang. Input RNA can also be in the form of long dsRNA or hairpin dsRNA that can be further cleaved by Dicer, an RNAase III enzyme, to generate a 21-nt-long siRNA that will form dsRNA-endonuclease complexes and will bind and destroy a specific mRNA target.
We transfected pLNCX/U6 and pLNCX/U6/gfp/ siRNA into phoenix cells to generate infectious retroviral particles that were subsequently used to infect other phoenix retroviral package cells that had previously been transfected with the GFP expression vector. Infection of the phoenix cells with the retroviral vector containing gfp/siRNA reduced expression of the fluorescence protein to nearly background levels, but no inhibition was noted for the cells infected with retroviral viral particles containing only the U6 promoter ( Figure 1b) . To explore the range of host cells subject to retrovirus-mediated siRNA gene silencing, we infected the retrovirus into two lung cancer cell lines, H1G299G1, H1G299G3, and breast cancer line G231, all of which have a stably integrated green fluorescence gene. In all three cell lines, GFP protein levels were no different between the parental cells and the cells infected with the pLNCX-U6 control, but GFP protein Silencing of H-ras gene expression by retrovirus-mediated siRNA in human ovarian cancer cell lines
We next tested whether retroviral-mediated gene expression could be used to silence H1-ras expression in human ovarian cancer cells. The H-ras gene is illustrated schematically in Figure 2a . We designed three siRNAs: H1/siRNA, which targets the H-rasV 12 mutation, and H2/siRNA and H3/siRNA, which target sequences in the wild-type H-ras. Nucleotides corresponding to each siRNA were synthesized and ligated into the pLNCX retroviral vector, and these vectors were used to infect T80H and SKOV-3 ovarian cancer cells. The T80H cell line is a genetically transformed, tumorigenic human ovarian surface epithelial cell line developed in our laboratory that expresses SV40 T/t, the catalytic subunit of human telomerase reverse transcriptase (hTERT), and H-rasV 12 . The tumorigenicity of T80H cells depends on the expression of H-rasV 12 (Liu et al., submitted) .
Both H1/SiRNA and H2/siRNA, and to a lesser extent, H3/siRNA, reduced H-ras protein expression in T80H cells (Figure 2b ). In SKOV-3 cells (a naturally derived ovarian cancer cell line that expresses high levels of Hras protein), the decrease in H-ras expression was drastic in H2/siRNA-infected cells, but not in H1/siRNAinfected or H3/siRNA-infected cells (Figure 2c ).
Slower proliferation and increased apoptosis in ovarian cancer cells that express H-ras siRNA Although the effect of the H-rasV 12 mutation on transformation and tumorgrowth has been widely studied, the effect of wild-type H-ras protein expression in human ovarian cancer cell lines has never been tested, partly because no specific inhibitors for wild-type H-ras protein have been available. Thus, we examined the effect of siRNA against H-ras after they infected target cells. Introduction of the H1/siRNA and H2/siRNAs into T80H cells led to substantial inhibition of proliferation, and H3/siRNA had a minimal effect ( Figure 3a ). With regard to SKOV-3 cells, only infection with the virus containing H2/siRNA showed a mild inhibition of cell proliferation; virus expressing H1/siRNA or H3/siRNA had no effect.
A critical function in H-ras-mediated transformation is the increase in resistance to apoptosis. We examined whether reducing the expression of H-ras protein would (Tabin et al., 1982) result in increased apoptosis. The number of apoptotic cells was increased among T80H cells infected with H1/ siRNA or H2/siRNA and among SKOV-3 cells infected with H2/siRNA retrovirus ( Figure 3b ). In quantitative terms, the percentage of apoptotic T80H cells was 18-21% in H1/siRNA-or H2/siRNA retrovirus-infected cells (vs 4% in controls), and the percentage of apoptotic SKOV-3 cells was 13% in H2/siRNA-infected cells (vs 3% in controls and in H1/siRNA-or H3/siRNAinfected cells) ( Figure 3c ). These results provide functional evidence that oncogenic mutation in H-ras and wild-type H-ras protein are important for cell proliferation and resistance to apoptosis.
Increased G 0 /G 1 and decreased S phase in ovarian cancer cells that express H-ras siRNA
We next examined whether slower proliferation is associated with changes in the cell cycles and the cell cycle regulatory proteins. As shown in Figure 4a , the proportion of cells in the G 0 /G 1 phase (M2) was significantly higher among the T80H cells that were infected with H1/siRNA (62.23%) or H2/siRNA retrovirus (53.78%) than among the U6-infected control cells (14%). The increase is associated with the concurrent decrease in S and G 2 /M phases. The increase in the proportion of the cell in the G 0 /G l phase was also seen in SKOV-3 cells infected with H2/siRNA retrovirus (53.19%), an effect that was associated with a concurrent decrease in S and G 2 /M phase. There was only a minimal change in the cell cycle associated with expression of H1/siRNA and only mildly increase in the G 0 /G 1 in H3/siRNA retrovirus-infected cells as compared with the U6 vector control. These data demonstrate that the H-ras/siRNAs slowed cell proliferation by increasing the cell population in G 0 /G 1 phase and reducing the number of cells in the synthetic phase.
We then tested several proteins that are involved in cell cycle control. As shown in Figure 4c , the expressions of Akt, phospho-Akt, p21, and cyclin Dl were decreased significantly lower in T80H cells infected with H1/ siRNA and H2/siRNA retrovirus than in U6 vector control (Figure 4c ). There was only a mild decrease in pAkt expression in H2/siRNA-infected, but not in H1-or H3/siRNA-retrovirus or U6 vector-infected, SKOV-3 cells. No change was observed in Akt, p21, or cyclin D1 expression.
H-ras siRNA expression decreases transformation efficiency in vitro and suppresses tumorigenicity in vivo
The hallmarks of H-ras are its ability to induce transformation in vitro and to stimulate tumor growth in vivo. We next examined how our three siRNA retroviruses would affect the transformation efficiency of T80H and SKOV-3 cells. As expected, the numbers of anchorage-independent growth colonies were markedly decreased in T80H cells infected with H1/siRNA or H2/siRNA retrovirus and in SKOV-3 cells infected with the H2/siRNA retrovirus (Figure 5a ). With regard to tumor growth, nude mice injected with T80H cells infected with control vector developed 100-mm 3 tumors in 6 weeks; injection of T80H cells infected with H1/siRNA or H2/siRNA showed only minimal tumor growth at that time (Figure 5b) . Similarly, injection of SKOV-3 cells infected with empty vector, H1/siRNA, or H3/siRNA retrovirus produced tumors in nude mice within 2 weeks, whereas SKOV-3 cells infected with H2/siRNA retrovirus showed minimal tumor growth (Figure 5b) . In quantitative terms, the drop in tumor volume in the mice injected with H1/ siRNA-or H2/siRNA retrovirus-infected T80H cells was more than 80%, and that in the mice injected with H2/siRNA-infected SKOV-3 cells was 50%.
Discussion
Previous studies have focused on identifying mutations in ras genes, particularly K-ras, that are common in mucinous or low-grade serous tumors of the ovary. However, very few studies have addressed the functional significance of such mutations. Also unclear is which members of the ras family (in addition to many growth factors and cytokines) are involved in activated ras signaling in high-grade serous carcinoma. In this paper, we began to address this issue by using stably expressed H-ras siRNA in human ovarian cancer cells. We found that H-ras expression was critically important for maintaining proliferation and inhibiting apoptosis and that H-ras siRNA can markedly reduce the efficiency of transformation in vitro and tumorgrowth in vivo. The siRNAs can increase G 0 /G 1 cell arrest and decrease the number of cells in the S and G 2 /M phases; such a change in the cell cycle is associated with a decrease in the proteins that facilitate cell cycle progression such as Akt, p21, and cyclin Dl in T80H cells. However, the level of proteins was not decreased, except for pAkt in the SKOV-3 cells infected with H2/siRNA. These results suggest that the H-ras uses different mechanisms to arrest the cells at G 0 /G 1 phase between two cell lines. This is not surprising, because T80H cells are genetically transformed ovarian surface epithelial cells, whereas SKOV-3 cells are naturally derived ovarian cancer cells and may use different pathways for cellular arrest. In a separate experiment (data not shown), we also found that H-ras protein was overexpressed roughly half of tumor specimens from 23 cases of high-grade human epithelial ovarian cancer, suggesting that H-ras plays an important role in human ovarian cancer development. DsRNA-dependent post-transcriptional silencing, also known as small inhibitory RNA (siRNA) or RNA interference (RNAi), is a phenomenon in which dsRNA silences the genes that are highly homologous to either strand of the RNA duplex. It has been recognized for several years that siRNA is a key mechanism of posttranscriptional silencing in the nematode Caenorhabditis elegans, in Drosophila, and in plants (Hammond et al., 2000) . Recent work has shown that siRNA can be used to silence genes in cultured human cells by introducing shorter synthetic duplex RNAs (i.e. 20 base pairs or less) through liposomal transfection. A 20-nucleotide siRNA is long enough to induce gene-specific silencing but short enough to evade host response (Elbashir et al., 2001) . Stable gene repression can also be achieved in mammalian cells by using plasmid vectors to express the RNA with a U6 or H1 promoter under the direction of RNA polymerase III (Miyagishi and Taira, 2002; Paddison et al., 2002a; Paul et al., 2002; Sui et al., 2002; Yu et al., 2002) . siRNA has also been shown to inhibit replication of the human immunodeficiency virus and the hepatitis virus through interference with its RNA genome (Jacque et al., 2002; McCaffrey et al., 2002) . Finally, retrovirus-mediated inference with K-rasV 12 has been shown to decrease the tumorigenicity of cancer cell lines (Brummelkamp et al., 2002) . These studies marked a new era in the genetic manipulation of human cancer development by allowing oncogenes to be downregulated through expression of single or multiple siRNAs.
We used a retroviral-based approach to deliver siRNA into tissue-cultured mammalian cells to inhibit the expression of a marker gene and the H-ras oncogene. The retroviral genome seemed to be immune from selfinduced interference, although the mechanism for this protective effect is not clear. The retroviral-mediated dsRNA silencing of gene expression should be generally applicable to other genes. Our results are consistent with others' findings that retroviruses can be a powerful delivery system for siRNAs (Barton and Medzhitov, 2002; Brummelkamp et al., 2002; Devroe and Silver, 2002; Paddison and Hannon, 2002) . We were able to target a specific mutation in the H-ras oncogene without affecting the expression of a nonmutated cellular gene. The H1/siRNA retrovirus was designed specifically against the H-rasV 12 oncogenic mutation, the fact that H-ras was silenced in T80H cells but not in SKOV-3 cells suggests that a single point mutation can significantly affect the efficiency of gene silencing. Our results suggest that H1/siRNA can inhibit mRNA containing H-rasV 12 mutation but not that of wild-type H-ras, while H2/siRNA can inhibit both H-rasV 12 as well as wildtype H-ras expression, while H3 is a poor functional siRNA that had only minimal effect on cellular function. These results may have important therapeutic implications. The ras oncogenes are most commonly mutated at codons 12, 13, and 63; specific siRNAs could be designed against each of these mutations and delivered according to the mutation status of each tumor. Alternatively, if a tumor does not have a ras mutation at any of these 'hot spots' but expresses high levels of wild-type H-ras, then the tumor could be treated with siRNA against wild-type H-ras, such as the H2 construct described in this paper. Efficient delivery of vector-based therapeutic genes in vivo remains an obstacle to successful gene therapy; but siRNA has the advantage over traditional gene therapy because it can be delivered as small-molecule oligonucleotides to bypass the limitation of delivery-associated gene therapy.
In summary, we have shown that siRNA against H-ras could block transformation and decrease tumorgrowth in human ovarian cancer cell models. Since the level of H-ras is high in high-grade serous carcinomas, it may be a potential target for therapy with siRNA, and an emerging new therapeutic tool for human cancer. 
Materials and methods
Vector constructions
The control retrovirus vectors were constructed as follows. The cytomegatovirus promoter in pLNCX was removed with BamH1 and Cla1 and replaced with U6 promoter from pBS/ U6 after digestion with BamHI and SmaI. pLNCX/U6/gfp/ siRNA was made by ligating BamH1 and Sma1 fragment containing U6 promoter and gfp/siRNA into the Bam H1 and Cla1 site in pLNCX after Cla1 was end-filled with Klenow enzyme. pBS/U6 and pBS/U6/gfp/siRNA were kind gifts of Dr Yang Shi of Harvard University and are described further elsewhere (Sui et al., 2002) . The following oligonucleotides were used. The loop sequence is indicated by lower case letters and underlined. The codon 12 is boldfaced and the single nucleotide change that contains mutant T rather than wildtype G is italicized. H1/siRNA (nt 29-50) sense: 5 0 GGCGCC GTCGGTGTGGGCAAGtctcttCTTGCCCACACCGACGG CGCC CTTTTTg-3 0 , antisense: 5 0 -aattc AAAAAGGGCGCC GTCGGTGTGGGCAAG aagaga CTTGCCCACACCGAC GGCGCC-3 0 ; H2/siRNA (nt 44-65) sense: 5 0 GGCAAGAGT GCGCTGACCATCtctctt GATGGTCAGCGCACTCTTGC CCTTTTT g-3 0 , antisense: 5 0 -aatt AAAAAGGGCAAGAGT GCGCTGACCATCaagagaGATGGTCAGCGCACTCTTG CC-3 0 ; and H3/siRNA (nt 89-109): sense: 5 0 -GGACGAATAC GACCCCACTAT tctctt ATA GTGGGGTCGTATTCGT CCCTTTTT g-3 0 , antisense: 5 0 -aattcAAAAAGGGACGAA TACGACCCCACTAT aagagaATAGTGGGGTCGTATTC GTCC-3 0 . The 3 0 end of the sense oligonucleotide contains g, and the 5 0 end of the antisense oligonucleotide contains aattc. Together, they form an end that can be ligated into an EcoR1 restriction enzyme recognition site. The 20 mm sense and antisense oligonucleotides were annealed in 10 Â buffer (100 mm Tris-HCl, pH 7.5, 1 m NaCl, 10 mm EDTA) and annealed at 681C for 1 h. The annealed DNA fragments were ligated into pBluescript/U6, which was first cut with ApaI, then blunted with Klenow enzyme and subsequently digested with EcoRI. After confirmation of the desired siRNA sequence in pBluescript/U6/siRNA, it was digested with BamHI and SmaI to release the DNA fragment containing U6/siRNA, which was subsequently ligated into pLNCX retroviral vector that was digested by Cla1, blunted with Klenow, and subsequently digested with BamHI.
Western blot analysis
Western blots were prepared and analysed as described elsewhere (Liu et al., 2000) . GFP expression was detected with the SC-8334 rabbit polyclonal antibody (Santa Cruz Biotechnology) at 1 : 2000 dilution. For H-ras, the primary antibody C20 was also from Santa Cruz Biotechnology; the secondary antibody was the NA 9340 anti-rabbit Ig horseradish peroxidase-linked F(ab) 2 fragment from donkey (Amersham Pharmacia Biotech, UK Limited). Western blot reagents were from an ECL kit (Amersham Pharmacia Biotech). The following antibodies were used: rabbit polyclonal antibody against total Akt (Cell Signaling Technology), Cat. #9272; 1 : 1000 dilution. Rabbit polyclonal antibody against ser 473 phosphorylated Akt (Cell Signaling Technology), Cat. #9271; 1 : 1000 dilution. Mouse monoclonal antibody against cyclin D1 (BD Pharmingen), Cat.#556470, 1 : 500 dilution. The mouse monoclonal antibody against p21 was a generous gift from Dr Wei Zhang, The University of Texas MD Anderson Cancer Center.
Cell lines and retroviral infection
The lung cancer cell lines, H1299G1, H1299G3, and breast cancer cell line G231 all of which included the green fluorescence gene were maintained in Dubecco's modified Eagle's medium (DMEM). The SKOV-3 ovarian cancer cell lines was from ATCC, RPMI 1640 (GIBCO). T80H cells were maintained in 105/l99 (1 : 1) medium; all media were supplemented with 10% fetal calf serum and 1% streptomycin and penicillin. The T80H cell line was derived from a tumor xenograph after normal ovarian surface epithelial cells were immortalized with SV40 large T and small t antigen (T/t) and the catalytic subunit of telomerase (hTERT). This immortalized cell line (T80) was subsequently infected with the retrovirus containing H-rasV 12 . Introduction of H-rasV 12 gene increased the H-rasV 12 protein to a level 5-10 times greater than in control precursor cell lines (Liu et al., submitted) . The human ovarian surface epithelial cells containing these three genetic elements are tumorigenic in nude mice. T80H cells were derived from tumors in nude mice that had been transformed with these three genetic elements. Retroviral packaging cells (phoenix amphotropic cells) were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained at 371C in Dubecco's DMEM containing 10% fetal bovine serum, 1 mm DMEM sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin (all from Sigma). To create amphotropic retrovirus, the phoenix cells were transfected by calcium-mediated transfection with 20-25 mg pLNCX/U6, pMN-IRES-EGFP (a retroviral construct expressing GFP protein, the gift of Gary Nolan, Stanford University), to create pLNCX/U6/gfp/siRNA. The medium was changed 9-12 h after transfection and the cells were incubated for another 12-14 h at 371C, after which the plates were moved to a 321C incubator to increase the viral titer. At 48 h after transfection, the supernatant was collected and spun at 3000 g for 3 min to remove residual phoenix cells. The supernatant was transferred to a new tube and filtered through a 0.45-mm syringe filter. The virus was either used fresh or stored at À801C until use. The target cells used for retrovirus infection were the cancer cell lines H1299G1, H1299G3, and G231 all of which included the GFP gene. Cells were cultured in 60-mm dishes; after the medium was removed, the plates were incubated for 24-48 h with 5 ml of a 1 : 4 mixture of virus supernatants and fresh culture medium containing 4 mg/ml of polybrene. The intensity of the green fluorescence was examined at 24 h after infection, and the protein was collected for Western blot analysis at 48 h.
Apoptosis assay
Cells (1 Â 10 4 ) were incubated for 48 h at 371C, stained with annexin V-FITC and propidium iodide, and visualized with a fluorescence microscope equipped with FITC and rhodamine filter sets. Apoptotic cells were counted automatically by the Meta Imaging System (Universal Imaging Corporation), which calculates and compares the red image area (apoptotic nuclei) against the green image area (background) with a template customized for each cell line. A total of 10-20 areas covering the complete slide chamber were included.
Cell proliferation assay
Cells (1 Â 10 4 ) were cultured for 16 h at 371C with 0.5 mCi [ 3 H] and then harvested onto glass-fiber filter paper and lysed in 5% trichloroacetic acid. The lysed samples were then dried and put into 10 ml of scintillation solution, after which incorporated [ 3 H]thymidine was measured with a Beckman LS6500 multipurpose scintillation counter.
Cell cycle detection
Cells (1-2 Â 10 6 ) were harvested and washed two times using 1X PBS and resuspended in 200 ml of 1X PBS. The cells were fixed using 4 ml of cold 75% ethanol at 41C for a minimum of 4 h and then washed two times with 1X PBS. The cells were then resuspended in 500 ml of 1X PBS, stained by addition of 200 ml of propidium iodide (50 mg/ml, Sigma) along with 20 ml of RNase (1 mg/ml, Sigma) in a 371C water bath for 15-20 min. Cell cycles were determined by FACS and analysed using CellQuest software.
Anchorage-independent cell-growth assay Cells (1 Â 10 4 ) were suspended in 2 ml of medium with 0.35% agarose (Life Technologies, Rockville, MD, USA) and the suspension placed on top of 5 ml of solidified 0.7% agarose. Triplicate cultures of each cell type were maintained for 14 days at 371C in a 5% CO 2 atmosphere, and fresh medium was added at 7 days. The number of colonies larger than 50 mm in diameter was counted at 14 days. These experiments were repeated twice.
Tumor growth
Equal numbers (5 Â 10 6 ) of T80H cells, SKOV-3 cells, and their derivatives infected with the U6, H1, H2, or H3 retroviruses were harvested by trypsinization, washed twice with lX phosphate-buffered saline, and resuspended in 0.1 ml of saline. Cells were then injected subcutaneously bilaterally into 4-6-week-old BALB/c athymic nude mice (Jackson Laboratory, Bar Harbor, ME, USA) with control cells or cells infected with retrovirus against H-ras. The mice were kept in pathogen-free environments and checked every 2 days for 2 months. The date at which grossly visible tumor first appeared and the size of the tumor were recorded. The mice were killed when tumors reached 1.5 cm in diameter.
